CN104903319B - 萘啶酮衍生物及其在治疗、改善或预防病毒疾病中的用途 - Google Patents

萘啶酮衍生物及其在治疗、改善或预防病毒疾病中的用途 Download PDF

Info

Publication number
CN104903319B
CN104903319B CN201480004147.6A CN201480004147A CN104903319B CN 104903319 B CN104903319 B CN 104903319B CN 201480004147 A CN201480004147 A CN 201480004147A CN 104903319 B CN104903319 B CN 104903319B
Authority
CN
China
Prior art keywords
alkyl
compound
oxo
dihydro
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201480004147.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN104903319A (zh
Inventor
A·沃尔克斯托弗
O·索拉尔
N·汉德勒
H·布施曼
S·丘萨克
M·史密斯
S-S·索
R·C·海利
A·希杜里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Savira Pharmaceuticals GmbH
F Hoffmann La Roche AG
Europaisches Laboratorium fuer Molekularbiologie EMBL
Original Assignee
Savira Pharmaceuticals GmbH
F Hoffmann La Roche AG
Europaisches Laboratorium fuer Molekularbiologie EMBL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Savira Pharmaceuticals GmbH, F Hoffmann La Roche AG, Europaisches Laboratorium fuer Molekularbiologie EMBL filed Critical Savira Pharmaceuticals GmbH
Publication of CN104903319A publication Critical patent/CN104903319A/zh
Application granted granted Critical
Publication of CN104903319B publication Critical patent/CN104903319B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201480004147.6A 2013-01-08 2014-01-07 萘啶酮衍生物及其在治疗、改善或预防病毒疾病中的用途 Expired - Fee Related CN104903319B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361750032P 2013-01-08 2013-01-08
US61/750,032 2013-01-08
PCT/EP2014/050168 WO2014108408A1 (en) 2013-01-08 2014-01-07 Naphthyridinone derivatives and their use in the treatment, amelioration or prevention of a viral disease

Publications (2)

Publication Number Publication Date
CN104903319A CN104903319A (zh) 2015-09-09
CN104903319B true CN104903319B (zh) 2017-05-31

Family

ID=50073147

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480004147.6A Expired - Fee Related CN104903319B (zh) 2013-01-08 2014-01-07 萘啶酮衍生物及其在治疗、改善或预防病毒疾病中的用途

Country Status (12)

Country Link
US (3) US9199987B2 (cg-RX-API-DMAC10.html)
EP (1) EP2945945B1 (cg-RX-API-DMAC10.html)
JP (1) JP2016504376A (cg-RX-API-DMAC10.html)
KR (1) KR20150103672A (cg-RX-API-DMAC10.html)
CN (1) CN104903319B (cg-RX-API-DMAC10.html)
BR (1) BR112015013414A2 (cg-RX-API-DMAC10.html)
CA (1) CA2894821A1 (cg-RX-API-DMAC10.html)
ES (1) ES2597803T3 (cg-RX-API-DMAC10.html)
HK (1) HK1211288A1 (cg-RX-API-DMAC10.html)
MX (1) MX2015008292A (cg-RX-API-DMAC10.html)
RU (1) RU2015132977A (cg-RX-API-DMAC10.html)
WO (1) WO2014108408A1 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3290424T1 (sl) 2015-04-28 2023-03-31 Shionogi & Co., Ltd. Substituirani policiklični piridonski derivati in njihovo predzdravilo
EP3428170B1 (en) 2015-04-28 2021-01-06 Shionogi & Co., Ltd Anti-influenza polycyclic pyridone derivative and prodrug thereof
CA3008607A1 (en) 2015-12-15 2017-06-22 Shionogi & Co., Ltd. A medicament for treating influenza characterized by combining a cap-dependent endonuclease inhibitor and an anti-influenza drug
UA125218C2 (uk) 2016-08-10 2022-02-02 Сіоногі Енд Ко., Лтд. Фармацевтичні композиції, що містять заміщені поліциклічні піридонові похідні та їх проліки
JP2020176263A (ja) * 2019-04-19 2020-10-29 住友化学株式会社 フィルム及び農園芸用施設

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020025960A1 (en) * 2000-07-12 2002-02-28 Bundy Gordon L. Heterocycle carboxamides as antiviral agents
WO2011041143A1 (en) * 2009-10-01 2011-04-07 Merck Sharp & Dohme Corp. HETEROCYCLIC-FUSED PYRAZOLO[4,3-c]PYRIDIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS
US20110166123A1 (en) * 2008-01-07 2011-07-07 Aardea Biosciences, Inc. Novel compositions and methods of use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5475109A (en) 1994-10-17 1995-12-12 Merck & Co., Inc. Dioxobutanoic acid derivatives as inhibitors of influenza endonuclease
CN101014572B (zh) 2004-09-15 2011-07-06 盐野义制药株式会社 具有hiv整合酶抑制活性的氨基甲酰基吡啶酮衍生物
TW200716632A (en) 2005-05-16 2007-05-01 Gilead Sciences Inc Integrase inhibitor compounds
TWI518084B (zh) 2009-03-26 2016-01-21 鹽野義製藥股份有限公司 哌喃酮與吡啶酮衍生物之製造方法
WO2010110231A1 (ja) 2009-03-26 2010-09-30 塩野義製薬株式会社 置換された３－ヒドロキシ－４－ピリドン誘導体
WO2011000566A2 (en) 2009-06-30 2011-01-06 Savira Pharmaceuticals Gmbh Compounds and pharmaceutical compositions for the treatment of negative-sense ssrna virus infections

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020025960A1 (en) * 2000-07-12 2002-02-28 Bundy Gordon L. Heterocycle carboxamides as antiviral agents
US20110166123A1 (en) * 2008-01-07 2011-07-07 Aardea Biosciences, Inc. Novel compositions and methods of use
WO2011041143A1 (en) * 2009-10-01 2011-04-07 Merck Sharp & Dohme Corp. HETEROCYCLIC-FUSED PYRAZOLO[4,3-c]PYRIDIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Heterocyclic fused pyridone carboxylic acid M1 positive allosteric modulators;Scott D. Kuduk et al.;《Bioorganic & Medicinal Chemistry Letters》;20100303;第20卷(第8期);第2533-2537页 *
Synthesis and structure-activity relationship studies of dihydronaphthyridinediones as a novel structural class of potent and selective PDE7 inhibitors;Rainer Gewald et al.;《Bioorganic & Medicinal Chemistry Letters》;20110921;第21卷(第22期);第6652-6656页 *

Also Published As

Publication number Publication date
BR112015013414A2 (pt) 2017-07-11
US20140194432A1 (en) 2014-07-10
CN104903319A (zh) 2015-09-09
CA2894821A1 (en) 2014-07-17
MX2015008292A (es) 2016-06-02
US9505758B2 (en) 2016-11-29
WO2014108408A1 (en) 2014-07-17
EP2945945B1 (en) 2016-08-31
EP2945945A1 (en) 2015-11-25
ES2597803T3 (es) 2017-01-23
RU2015132977A (ru) 2017-02-14
JP2016504376A (ja) 2016-02-12
US20160039818A1 (en) 2016-02-11
US20170290834A1 (en) 2017-10-12
HK1211288A1 (en) 2016-05-20
US9199987B2 (en) 2015-12-01
KR20150103672A (ko) 2015-09-11

Similar Documents

Publication Publication Date Title
CN103958521B (zh) 嘧啶-4-酮衍生物及其在治疗、减轻或预防病毒疾病中的用途
CN104334563B (zh) 7‑氧代‑噻唑并吡啶碳酸衍生物和它们在治疗、改善或预防病毒疾病中的用途
KR20150039832A (ko) 디하이드록시피리미딘 탄산 유도체 및 바이러스성 질환의 치료, 개선 또는 예방에서의 이의 용도
CN104903294A (zh) 吡啶酮衍生物及其在治疗、改善或预防病毒疾病中的用途
JP2016518305A (ja) ピリミドン誘導体及びウイルス性疾患の治療、改善又は予防におけるそれらの使用
CN103958475B (zh) 杂芳基异羟肟酸衍生物及其在治疗、减轻或预防病毒疾病中的用途
KR20150014506A (ko) 바이러스성 질환의 치료, 개선 또는 예방에서 유용한 7-옥소-4,7-디하이드로-피라졸로[1,5-a]피리미딘 유도체
CN104903319B (zh) 萘啶酮衍生物及其在治疗、改善或预防病毒疾病中的用途
CN107074880A (zh) 二氢吡啶并吡嗪‑1,8‑二酮和它们在治疗、改善或预防病毒疾病中的用途
US20170081331A1 (en) Pyrazolopyrazines and their use in the treatment, amelioration or prevention of a viral disease
CN107001355A (zh) 吡啶并吡嗪化合物和它们在治疗、改善或预防流感中的用途
KR20210038908A (ko) 인플루엔자바이러스 복제 억제제로서의 피롤로[2,3-b]피리딘 유도체

Legal Events

Date Code Title Description
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1211288

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20170531

Termination date: 20180107

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1211288

Country of ref document: HK